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Results | From 1988 to 1998, the incidence of thyroid cancer had an annual percentage increase of 3.0%. The trend accelerated to 6.7% from 1998 to 2009 and then stabilized from 2010 to 2012 at 1.75% (95% CI, −1.90 to 5.54; P = .01 for the change in trend) (Figure) . These trends were unchanged when rates of thyroid cancer were adjusted for delayed reporting. The stabilization in incidence rates from 2010 to 2012 remained when tumors were stratified by size and was most pronounced for tumors of subcentimeter size (Table) . Discussion | The rapidly rising incidence of thyroid cancer in the United States has been recognized as an "epidemic of diagnosis" more than an epidemic of disease. Acknowledging this, practice guidelines are becoming increasingly nuanced in recommendations about which nodules to biopsy. The data reported here suggest that clinical practices are also changing, as reflected by the beginning of stabilization of the previously rapidly rising incidence of thyroid cancer in the United States. Notably, rates of detection of subcentimeter cancers, previously increasing at more than 9% per year, have stabilized. 
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Data are expressed per 100 000 persons and age-adjusted to the 2000 US population. Data markers represent observed incidence rates; lines, the joinpoint-modeled regression lines; and percentages, the annual percentage change (Table) .
These data cannot provide causal evidence of a link between trends in the incidence of thyroid cancer and specific clinical practice guidelines. Nevertheless, the data suggest that changing clinical practices are responsible for the slowing increase in the reported incidence of thyroid cancer. Statistical testing showed positive inflection points (an accelerating incidence of thyroid cancer) in the 1990s and a negative inflection point (a decelerating incidence) after 2009. During the 1990s and 2000s, no known biological risk factors for thyroid cancer have increased and then decreased. More likely, the trends in the incidence of thyroid cancer are due to shifts in medical practices. Some might argue that the incidence of thyroid cancer is now reaching a plateau near that of the prevalence of subclinical thyroid cancers in the US population, but this theory requires further investigation because the reservoir of subclinical thyroid cancers has been estimated as being much larger than the current incidence. The next few years will determine if this stabilization is durable. The 2015 American Thyroid Association guidelines further refine indications for the biopsy of thyroid nodules. This refinement may lead to a decline in the reported incidence of thyroid cancer, resembling the reversal observed in South Korea as the result of public awareness of the overdiagnosis of thyroid cancer.
4 These trends will have substantial public health ramifications with determination of the appropriate level of aggressiveness in detecting and treating low-risk thyroid cancers.
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COMMENT & RESPONSE

Screening and Follow-up of Children Who Snore When Polysomnography Is Not Available
To the Editor We read with great interest the article titled "The Role of Sleep Studies in Children Who Snore" by Ishman. 1 In this article the author reaffirmed the importance of performing polysomnography in children with suspected sleep disordered breathing (SDB) before and especially after treatment because the risk of persistent obstructive sleep apnea (OSA) after surgery is high. Moreover, the high cost and the limited availability of these studies is quite correctly pointed out by the author. It seems that there is no hope for these children to be studied if polysomnography is not available because, as the author states, medical history and physical examination have a positive and negative predictive value that is not sufficient to establish an OSA diagnosis. Our group has recently validated the sleep clinical record (SCR), which can be easily used in settings with limited resources.
2 It consists of 3 items: physical examination, subjective symptoms, and clinical history, inclusive of behavioral and cognitive problems. All 3 items were used to create an overall score. If this is 6.5 or greater it has a sensitivity of 96.05% in diagnosing OSA. Positive and negative likelihood ratios were 2.91 and 0.06, respectively. Moreover, if nocturnal oximetry testing is available, the combination of SCR score and McGill oximetry scores has moderate success in predicting SDB severity when PSG testing is not an option.
3
The author also pointed out the importance of the identification of persistent OSA after adenotonsillectomy (AT), because persistent OSA has deleterious effects on neurocognitive and cardiovascular function. Once again we have recently demonstrated that the SCR can be a potentially useful instrument for follow-up of children with OSA after treatment. 4 Looking at the 2 main OSA treatments (AT and orthodontic therapy with RME), all patients with residual OSA at the PSG had a positive SCR, resulting in a positive predictive value of 100%. We agree with the author that PSG is the gold standard for definitively diagnosing OSA and we are conscious of the high cost and limited availability of sleep laboratories. The literature is still lacking in accurate, cheap, and easily available tools to identify patients who need therapy as soon as possible when PSG is not available. We think that SCR and nocturnal oximetry testing can be valid tools that can be used by all clinicians in the screening and follow-up of "children who snore."
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